Abstract
Pancreatic cancer is one of the most lethal types of cancer, due to difficulty in early detection and the limited efficacy of available treatments. Erlotinib is used to inhibit the epidermal growth factor receptor for the treatment of pancreatic cancer; however, erlotinib resistance is a major issue and the mechanisms underlying the development of erlotinib resistance remain unclear. To better understand the alterations in tumor metabolism by acquired resistance to erlotinib, an erlotinib-resistant pancreatic cancer cell line (HPAC-ER) was established, followed by a comparison of the metabolic characteristics between these cells and their erlotinib-sensitive parental cells (HPAC). This comparison was accomplished through mass spectrometry-based targeted metabolic profiling. Five metabolite groups (acylcarnitines, amino acids and biogenic amines, glycerophospholipids, sphingolipids and monosaccharides) were semi-quantified and compared statistically. These results revealed significant differences between the two groups of cells. A significant increase in the level of short-chain acylcarnitines and selected lysophosphatidylcholines, and a significant decrease in the level of acyl-alkyl-phosphatidylcholines and one sphingolipid, w...Continue Reading
References
Jul 6, 1992·Molecular and Cellular Biochemistry·M A MedinaI Núñez de Castro
Dec 1, 1974·Cell·V H Freedman, S I Shin
Jun 17, 2000·Biochimica Et Biophysica Acta·J Kerner, C Hoppel
Sep 11, 2003·Analytical Chemistry·B K MatuszewskiC M Chavez-Eng
Oct 19, 2005·Cancer Research·Egidio IorioFranca Podo
Apr 25, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malcolm J MooreUNKNOWN National Cancer Institute of Canada Clinical Trials Group
May 29, 2007·Biochemical Pharmacology·Brian S Cummings
Sep 1, 2009·Advanced Drug Delivery Reviews·Victor A ZammitArduino Arduini
Apr 30, 2010·The New England Journal of Medicine·Manuel Hidalgo
May 18, 2010·International Journal of Cancer. Journal International Du Cancer·Masanori YoshimatsuRyuji Hamamoto
Jul 6, 2010·Drug Discovery Today·Miroslava Cuperlović-CulfIan Chute
May 31, 2011·Lancet·Audrey VincentMichael Goggins
Dec 14, 2011·Analytica Chimica Acta·Georgios A TheodoridisIan D Wilson
Jun 12, 2012·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Mariska DavidsTom Teerlink
Jun 30, 2012·The International Journal of Biochemistry & Cell Biology·Pratima TripathiAyyalusamy Ramamoorthy
Jul 31, 2012·Biochimica Et Biophysica Acta·Nadège BellanceDeepak Nagrath
Aug 14, 2012·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Jens Martens-Lobenhoffer, Stefanie M Bode-Böger
Dec 13, 2012·Oncology Reports·Shinsuke SasadaMorihito Okada
Jun 1, 2013·Journal of Applied Toxicology : JAT·Mounir BouhifdLiang Zhao
Oct 5, 2013·Cell Death & Disease·H LiW Jia
Feb 13, 2014·Pancreas·Yoshinori FujimuraMasao Tanaka
Oct 2, 2014·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Marloes A M PetersSjoukje F Oosting
Feb 24, 2015·The Journal of Biological Chemistry·Claudia StäubertAnders Nordström
Citations
Dec 2, 2017·Oncotarget·Won-Jun JangChul-Ho Jeong
Sep 20, 2019·Metabolites·Naeun LeeChul-Ho Jeong
Jul 10, 2019·CNS Neuroscience & Therapeutics·Neelesh DewanKunjan R Dave
Jul 28, 2020·Metabolites·Xun ChenDongsheng Yu
Aug 28, 2021·Cancers·Helena A HerrmannJürgen Zanghellini